Regeneron Pharmaceuticals Inc. is experiencing a notable uptick in its stock price, driven by positive developments in its partnerships and pipeline.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is rising today, gaining 2.28% to close at CA$763.55. The company is benefiting from recent announcements surrounding its collaborations and advancements in its drug pipeline, which have bolstered investor confidence.
Investor takeaway: Investors are encouraged by Regeneron's strategic partnerships and the potential for new revenue streams from its expanding drug pipeline, particularly in oncology and immunology.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$76.86B
P/E
18.5x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$551.04
1W change
+1.54%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 12, 2026
Wall Street analysts forecast REGN stock price to rise 15.1% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.04
+15.1% Upside
Previously C$856.23 on Oct 9, 2026
Current Price
C$746.54
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.3%
Annualized
90-Day Vol
29.2%
Annualized
Trend (90d)
+40.4%
Annualized drift
90d Mean
C$862.28
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$783.28 | C$710.45 – C$863.58 |
| 60 trading days | C$821.83 | C$715.88 – C$943.46 |
| 90 trading days | C$862.28 | C$728.17 – C$1021.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Regeneron’s Market Cap Reaches CA$76.86 Billion
With a robust market cap of CA$76.86 billion, Regeneron is well-positioned to leverage its strong pipeline and collaborations to drive future growth.
Bull case
The expanded collaboration with Sanofi, which could be worth up to $8 billion, positions Regeneron to enhance its pipeline with next-generation therapies. This partnership could lead to significant revenue growth in the future.
Bear case
Despite the positive momentum, investors should be cautious about potential earnings challenges from the recent Sanofi deal. This could impact profitability in the short term.
Strategic Collaborations Boost Investor Confidence
Advertisement
Regeneron recently expanded its long-standing collaboration with Sanofi, which includes an upfront payment of $1 billion and potential future milestone payments of up to $7 billion. This partnership is expected to enhance Regeneron's pipeline, particularly in immunology and oncology, providing a pathway for future revenue growth.
Pipeline Developments Signal Future Growth
The company has reported promising clinical data across its oncology and obesity programs, which are crucial for diversifying its revenue streams. As Regeneron continues to innovate and expand its offerings, investors are optimistic about the potential for significant market opportunities.
Earnings Impact from Sanofi Deal
While the expanded collaboration presents growth opportunities, it also brings potential earnings challenges, with Regeneron estimating a $0.18 per share impact in Q3 2026 due to related charges. Investors should weigh these factors as they consider the stock's future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
